Why BioMarin (BMRN) is Poised to Beat Earnings Estimates Again

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering BioMarin Pharmaceutical (BMRN) , which belongs to the Zacks Medical - Biomedical and Genetics industry. For the last reported quarter, BioMarin came out with earnings of $0.71 per share versus the Zacks Consensus Estimate of $0.60 per share, representing a surprise of 18.33%. For the previous quarter, the company was expected to post earnings of $0.44 per sha ...